What is Vilon?

A synthetic immunoregulatory dipeptide (Lys-Glu) studied in thymic and splenic cell cultures.

Vilon in the library · Bioregulator Peptides · Human Trials · What are peptides?

0 registered trials · 2 indexed papers · 14 human / 43 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

Vilon is described as a synthetic immunoregulatory dipeptide made of lysine and glutamic acid (Lys-Glu). Preclinical research is described as indicating it may raise immune markers including CD5+ lymphocytes and interleukin-2 expression in thymic and splenic cell cultures.

It belongs to a class of short bioregulatory peptides developed through Russian gerontology research. In vitro studies are described as showing the dipeptide can modulate lymphocyte populations and cytokine gene expression.

Peer-reviewed studies (2)

PaperAuthorsJournalYearType
[Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus]Kuznik BI et al.Advances in gerontology = Uspekhi gerontologii2007Clinical Trial
[Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age]Kuznik BI et al.Advances in gerontology = Uspekhi gerontologii2006Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Vilon?

A synthetic immunoregulatory dipeptide (Lys-Glu) studied in thymic and splenic cell cultures.

How many registered human trials study Vilon?

The PeptideWhiz trial index lists 0 registered trials for Vilon.

How much published research exists on Vilon?

The PeptideWhiz paper index links 2 PubMed papers to Vilon; by study type, 14 human and 43 animal studies.

Which conditions is Vilon researched for?

Insulin resistance, prediabetes & type 2 diabetes.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).